cancer treatment. From diagnosis
to therapy in 3-7 days!
cancer treatment. From diagnosis
to therapy in 3-7 days!
cancer treatment. From diagnosis
to therapy in 3-7 days!
Deliver the first true personalized cancer treatment
Mission
Business model
Mission
Deliver the first true personalized cancer treatment. From diagnosis to therapy in 3-7 days!
Business model
Apoliktos is establishing a platform, which uses a modular library of neoantigen binders and antibody backbones connected at the patient’s bedside for targeted personalized therapeutic antibodies.
Cancer patients can’t afford to wait for the next personalized drug to be made once they have been diagnosed
IP
The IP space has been cleared and a provisional patent application is in filing stage.
The Company
The designated 4 co-founders Laure Bouchez , Guido Koch, Nicolas Melin and Javier Asenjo are entrepreneurial experts with strong track records in drug discovery and development.
Apoliktos neo concept - A personalized therapy in 3 to 7 days
In Apoliktos, we are working on a novel neoantigen concept against cancer. We aspire to help develop a personalized therapy for patients in 3 to 7 days.
First, with the help of the physician, we would evolve the diagnostic and perform a patient stratification.
Then, we would be able to develop a personalized patient approach using specific tumor-mutation binders that, combined with the immune-therapy, would improve dramatically the approach. This combination would happen right at the bedside.
Finally, the patient would receive a heavily personalized immune-therapy treatment.
research
1
%
Biotech
1
%
science
1
TEAM
Dr. Laure C. Bouchez 
Drug hunter with a strong track record of over 7 clinical candidates (from stem cell therapy to small molecules and currently filing an IND for a bispecific biologics) and co-author on 10 patents. Published over 40 peered publications and reviews.
Since March 2019. Director, Project team leader Biologics at Glenmark/Ichnos Pharmaceuticals: focusing on areas of developmental and immune processes which hold promise for clinical application.
2011-2019 Research Laboratory Head at NIBR: drug hunter on multiple projects from regenerative medicine to inflammation and oncology.
Dr Guido Koch
Drug hunter and entrepreneur – key contributions to 1 marketed product and 8 clinical candidates. Small molecules, natural products & new modalities. Author or co-author of >45 publications & 10 patents.
Since 2020, Co-founder and CEO Amphilix AG – discovery and development of chimeric small molecules for the treatment of complex diseases.
2018-2020 COO Topadur Pharma AG; Developing biotech startup into a clinical stage venture.
1997-2018 Novartis, Director Global Discovery Chemistry; Immunology, Infectious diseases, drug discovery technology platforms, natural products.
Dr Nicolas Melin
Biologist with 10-year expertise in-vitro assay development and in-vivo tumor model.
Since September 2020 Post Doctoral Fellow at the Visceral and transplantation surgery group of the University of Bern: working on the metabolic changes occurring during liver regeneration.
2014-2020 PhD student at the Visceral and transplantation surgery group of the University of Bern: working on developing critical in-vitro and in-vivo models allowing to understanding radiation-induced liver disease.
2010-2013 Research associate at NIBR: screening, in-vitro pharmacology target validation and assay development.
Javier Asenjo
Technologist, Entrepreneur and investor with experience in tech management roles across industries and a track record of founding businesses in Spain and Germany.
Early investor (with exits) in multiple tech starts ups in the US and India.
2022-Present Technology management in Sportswear /consumer good industry
2009-2021 Technology management roles in Healthcare/Pharmaceutical companies
2007-2009 Accenture Technology Consultant and Founder